Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Final Trades: Amazon, ScottsMiracle-Gro, Abbvie and the SPHD
01:23pm, Thursday, 01'st Aug 2024
The Investment Committee give you their top stocks to watch for the second half.
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
12:46pm, Thursday, 01'st Aug 2024
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
AbbVie Completes Acquisition of Cerevel Therapeutics
08:23am, Thursday, 01'st Aug 2024
Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class,
2 Stocks With Potential To Become Great Long-Term Investments
09:00am, Wednesday, 31'st Jul 2024
Long-term outlook is crucial in investing, short-term gains may be attractive but can turn out to be bad if continued. AbbVie is a successful example of a newly-listed company that has turned out to b
7 Stocks Set for a Major Bull Run
06:22am, Wednesday, 31'st Jul 2024
Understanding companies' fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages.
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
06:15am, Wednesday, 31'st Jul 2024
Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate.
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
12:17pm, Tuesday, 30'th Jul 2024
AbbVie NYSE: ABBV was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader range of
5 Dividend Aristocrats May Be Primed for a Big August
11:20am, Tuesday, 30'th Jul 2024
24/7 Insights Dividend Aristocrat shareholders could see some big upside in August.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:06am, Tuesday, 30'th Jul 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day
08:00am, Tuesday, 30'th Jul 2024
Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024 Members receive an exclusive gift card offer and a chance to win $10,000* IRVINE, Calif.
Pharma companies less concerned after hearing from US on negotiated prices for Medicare
01:37pm, Monday, 29'th Jul 2024
Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential su
AbbVie: Growth Is Still A Better Choice
12:19pm, Monday, 29'th Jul 2024
On July 25, AbbVie released its Q2 2024 financial results, which surprised me with surging sales of its immunology and neuroscience franchises. So, Rinvoq's sales amounted to $1.43 billion for the thr
3 High-Yield Dividend Stocks That Are Looking Super Hot
09:50am, Monday, 29'th Jul 2024
High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend in
AbbVie: Q2 Earnings Validate Bullish Case
09:10am, Sunday, 28'th Jul 2024
AbbVie's recent Q2 earnings release was robust, validating my initial bullish thesis, which has aged well as the stock has outperformed the broader market since mid-April. The Q2 earnings release stre
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
02:54pm, Friday, 26'th Jul 2024
On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
